Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1654 1675
This examiner grants 63% of resolved cases
Christina Bradley is an examiner in Tech Center 1600 and Art Unit 1654, with 1040 resolved cases. Her allowance rate is 62.6 percent. A standout feature of her profile is the interview lift of 33.3 percent, which indicates that oral advocacy is extremely effective in this docket.
The data suggests that interviews are a critical component of a successful prosecution strategy. An interview lift of 33.3 percent indicates that applicants who engage in direct dialogue are much more likely to secure a grant than those who rely solely on written responses. This is particularly relevant given the 62.6 percent baseline allowance rate across the 1040 resolved cases.
The median days to allowance is 986, reflecting a significant duration for applications to reach a final resolution. Practitioners should anticipate a standard process but can use the 33.3 percent interview lift to navigate the 986-day period more effectively. The high volume of 1040 resolved cases provides a robust statistical foundation for these insights in Art Unit 1654.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18673424 | Combination Therapy for Treatment of Liver Disease | Non-Final OA | Novo Nordisk A/S |
| 18252056 | COMPOUNDS AND THEIR USE IN TREATMENT OF TACHYKININ RECEPTOR MEDIATED DISORDERS | Non-Final OA | Novo Nordisk A/S |
| 18551557 | K-RAS INHIBITOR | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 17920698 | INHIBITION OF SARS-COV-2 VIRAL ENTRY THROUGH ORAL ADMINISTRATION OF LACTOFERRIN AND USES THEREOF | Non-Final OA | The Regents of the University of Michigan |
| 19341996 | PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST | Final Rejection | ELI LILLY AND COMPANY |
| 19338984 | PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST | Final Rejection | ELI LILLY AND COMPANY |
| 17909689 | PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS | Final Rejection | Sanofi |
| 17914207 | FIBRILLATION RESISTANT CALCITONIN PEPTIDES AND USES THEREOF | Final Rejection | Purdue Research Foundation |
| 18283112 | REGULATORY T CELL-INDUCING PEPTIDE AND COMPOSITION INCLUDING SAME FOR PREVENTING OR TREATING AUTOIMMUNE DISEASE | Non-Final OA | IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) |
| 17766884 | IMMUNOGLOBULIN PURIFICATION PEPTIDES AND THEIR USE | Non-Final OA | North Carolina State University |
| 18556402 | SMALL HYDROPHOBIC PROTEIN DRUG CONJUGATES AND USES THEREOF | Non-Final OA | DANMARKS TEKNISKE UNIVERSITET |
| 18250977 | INHIBITORS OF ANGIOGENIC FACTORS | Non-Final OA | Hoffmann-La Roche Inc. |
| 18266882 | ANTAGONIST OF INTERLEUKIN-17B RECEPTOR (IL-17RB) AND USE THEREOF | Non-Final OA | Academia Sinica |
| 17915976 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MUCOSITIS INDUCED BY RADIOTHERAPY, CHEMOTHERAPY, OR COMBINATION THEREOF, COMPRISING GLP-2 DERIVATIVES OR LONG-ACTING CONJUGATE OF SAME | Final Rejection | HANMI PHARM. CO., LTD. |
| 18850815 | PEPTIDE HAVING ANTI-INFLAMMATORY AND ANTI-FIBROTIC ACTIVITIES AND USE THEREOF | Non-Final OA | CAREGEN CO., LTD. |
| 18836305 | GLP-1 AND GLUCAGON DUAL AGONIST PEPTIDES WITH IMPROVED BIOLOGICAL STABILITY | Non-Final OA | MEDIMMUNE LIMITED |
| 18560230 | METHODS FOR INCREASING RED BLOOD CELL HALF-LIFE AND ASSOCIATED TREATMENT OF ANEMIA | Non-Final OA | Marshall University Research Corporation |
| 18053765 | LIQUID BANDAGE CONTAINING PEPTIDE ANTI-INFLAMMATORY ACTIVE INGREDIENTS AND PREPARATION METHOD THEREOF | Non-Final OA | ZHEJIANG OCEAN UNIVERSITY |
| 18267608 | RECOMBINANT CD3 BINDING PROTEINS AND THEIR USE | Non-Final OA | MOLECULAR PARTNERS AG |
| 18118120 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL HORMONE SUPPLEMENTATION | Final Rejection | Xygenyx Inc. |
| 18116849 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL HORMONE SUPPLEMENTATION | Non-Final OA | Xygenyx Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy